HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. (6986) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.104x
Based on the latest financial reports, HeXun Biosciences Co., Ltd. (6986) has a cash flow conversion efficiency ratio of 0.104x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$73.42 Million) by net assets (NT$703.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HeXun Biosciences Co., Ltd. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how HeXun Biosciences Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HeXun Biosciences Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HeXun Biosciences Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hantech Bio-Technology Co., Ltd.
TWO:1294
|
N/A |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
-0.077x |
|
Q32 Bio Inc
NASDAQ:QTTB
|
0.229x |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
N/A |
|
Articore Group Ltd
AU:ATG
|
-1.004x |
|
Metacon AB
ST:META
|
-0.611x |
|
THINKWARE Corporation
KQ:084730
|
0.070x |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
-0.106x |
Annual Cash Flow Conversion Efficiency for HeXun Biosciences Co., Ltd. (2021–2024)
The table below shows the annual cash flow conversion efficiency of HeXun Biosciences Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$620.58 Million | NT$120.92 Million | 0.195x | +114.05% |
| 2023-12-31 | NT$473.36 Million | NT$43.09 Million | 0.091x | +155.28% |
| 2022-12-31 | NT$314.87 Million | NT$11.23 Million | 0.036x | +121.57% |
| 2021-12-31 | NT$214.75 Million | NT$-35.50 Million | -0.165x | -- |